Gillham C M, Aherne N, Rowley S, Moore J, Hollywood D, O'Byrne K, Reynolds J V
Academic Unit of Clinical and Molecular Oncology, Trinity Centre, St James's Hospital, Dublin, Ireland.
Clin Oncol (R Coll Radiol). 2008 Apr;20(3):227-33. doi: 10.1016/j.clon.2007.12.002. Epub 2008 Jan 14.
To report cancer-specific and health-related quality-of-life outcomes in patients undergoing radical chemoradiation (CRT) alone for oesophageal cancer.
Between 1998 and 2005, 56 patients with oesophageal cancer received definitive radical CRT, due to local disease extent, poor general health, or patient choice. Data from European Organization for Research and Treatment of Cancer quality-of-life questionnaires QLQ-30 and QLQ-OES24 were collected prospectively. Questionnaires were completed at diagnosis, and at 3, 6 and 12 months after CRT where applicable.
The median follow-up was 18 months. The median overall survival was 14 months, with a 51, 26 and 13% 1-, 3- and 5-year survival, respectively. At 12 months after treatment there was a significant improvement compared with before treatment with respect to dysphagia and pain. Global health scores were not significantly affected.
Considering the relatively short long-term survival for this cohort of patients, maximising the quality of those final months should be very carefully borne in mind from the outset. The health-related quality-of-life data reported herein helps to establish benchmarks for larger evaluation within randomised clinical trials.
报告仅接受根治性放化疗(CRT)的食管癌患者的癌症特异性及与健康相关的生活质量结果。
1998年至2005年间,56例食管癌患者因局部疾病范围、总体健康状况差或患者选择而接受了根治性CRT。前瞻性收集了来自欧洲癌症研究与治疗组织生活质量问卷QLQ - 30和QLQ - OES24的数据。问卷在诊断时以及CRT后3、6和12个月(如适用)完成。
中位随访时间为18个月。中位总生存期为14个月,1年、3年和5年生存率分别为51%、26%和13%。治疗后12个月,吞咽困难和疼痛较治疗前有显著改善。总体健康评分未受到显著影响。
考虑到该组患者相对较短的长期生存期,从一开始就应非常谨慎地牢记要最大限度提高最后几个月的生活质量。本文报告的与健康相关的生活质量数据有助于在随机临床试验中为更大规模的评估建立基准。